1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Fate Therapeutics, Inc.

Fate Therapeutics, Inc.

FATE
Fate Therapeutics, Inc.US flagNASDAQ Global Market
2.11
USD
+0.25
- -
245.36MMarket Cap
Fate Therapeutics, Inc.
FATE
(NASDAQ Global Market)

Recent

price

2.11

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.13
0.3
0.16
- -
0.1
0.14
0.1
0.08
0.16
0.38
0.59
0.99
0.65
0.12
0.06
0.05
Revenue per Share
-1.51
-1.61
-3.54
-1.27
-1.18
-1.05
-1.02
-1.19
-1.44
-2.1
-2.24
-2.91
-1.64
-1.64
-1.15
-1.05
Basic EPS, GAAP
-1.37
-1.58
-2.65
-1.14
-0.78
-0.95
-0.92
-0.73
-1.33
-0.54
-2.25
-2.93
-1.41
-1.09
-0.94
-0.88
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-2.65
-5.71
2.49
1.38
1.32
1.77
1.47
2.48
3.23
4.38
7.09
4.97
3.74
2.8
1.8
1.31
Book Value per Share
-2.65
-5.71
2.49
1.38
1.32
1.77
1.47
2.48
3.23
4.38
7.09
4.97
3.74
2.8
1.8
1.31
Tangible Book Value per Share
9
9
6
20
25
32
42
56
68
82
95
97
98
114
119
120
Basic Weighted Avg Shares
1
3
1
- -
2
4
4
5
11
31
56
96
64
14
7
6
Sales/Revenue/Turnover
-1,136.15
-507.75
-1,820.29
- -
-1,142.82
-726.1
-1,025.94
-1,415.44
-943.14
-407.47
-388.56
-320.23
-299.86
-1,434.52
-2,222.45
-2,058.08
Operating Margin (%)
1
1
1
- -
1
1
1
1
2
3
6
14
18
19
13
12
Depreciation Expense
-13
-14
-21
-26
-30
-33
-43
-67
-98
-173
-212
-282
-161
-186
-136
-126
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-1,147.61
-533.3
-2,151.8
- -
-1,233.73
-760.15
-1,046.08
-1,405.02
-919
-551.59
-379.89
-292.55
-253.3
-1,366.46
-2,051.08
-1,941.09
Profit Margin (%)
3
5
50
45
52
78
92
178
199
409
552
388
292
253
173
125
Working Capital
4
2
- -
18
11
3
15
12
25
94
109
104
97
78
73
71
LT Debt
-51
-53
51
28
38
73
77
160
245
384
679
484
368
319
207
153
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-65.37
-90.37
-60.19
-57.14
-56.05
-48.44
-55.11
-39.91
-48.46
-37.76
-54.21
-51.84
-60.75
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
5
5
5
LT Borrowings
- -
- -
- -
LT Finance Leases
73
72
71
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
115
116
117
Market Capitalization
113
140
315

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
209
180
158
Cash, Cash Equivalents & STI
204
175
154
Accounts Receivable, Net
1
1
1
Inventories
- -
- -
- -
Total Current Liabilities
36
31
33
Payables & Accruals
23
17
18
ST Debt
5
5
5
Deferred Revenue
- -
1
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
29.08%
-4.9%
-35%
Free Cash Flow
50.09%
69.04%
-9.36%
Net Income, GAAP
22.02%
0.24%
-26.82%
Sales/Revenue/Turnover
39.57%
-2.74%
-51.24%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2
7
3
2
14
2025
2
2
2
1
7
2026
1
2
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.47
-0.33
-0.4
-0.44
-1.64
2025
-0.32
-0.29
-0.27
-0.27
-1.15
2026
-0.26
-0.25
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Exscientia plc (EXAI)
Niki BioSolutions, Inc. (NIKI)
InMed Pharmaceuticals Inc. (IN.TO)
60 Degrees Pharmaceuticals, Inc. (SXTP)
ContraFect Corp. (CFRXQ)
Hillstream BioPharma, Inc. (HILS)
Business
Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical-stage biopharmaceutical company that develops off-the-shelf, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies, including multiplexed-engineered T-cell and natural killer (NK) cell product candidates incorporating novel synthetic controls of cell function for the treatment of cancer and autoimmune diseases; its pipeline features FT819 (CD19 CAR T-cell with FDA RMAT designation in systemic lupus erythematosus), FT522 (CD19/CD20 CAR NK cell), FT839 (next-generation CD19/CD38/CD20 CAR T-cell), FT836 (next-generation multi-antigen CAR T-cell targeting MICA/B/EGFR/HER2 for solid/hematologic malignancies and CD19/CD38/BCMA/GPRC5D for hematologic malignancies), and FT825 (HER2/EGFR CAR NK cell), among others in Phase 1 for indications such as systemic lupus erythematosus, systemic sclerosis, ANCA-associated vasculitis, idiopathic inflammatory myopathies, and solid tumors. Founded in 2007 and headquartered in San Diego, California, the company conducts research, development, clinical operations, and cGMP manufacturing from its facilities there, with operations focused on the United States and recent expansion of clinical trial sites to the EU and UK. Latest developments include FDA IND allowance and Phase 1 initiation for FT836 in solid tumors, MHRA and EMA authorization to open ex-US sites for FT819 autoimmune trials, promising Phase 1 data for FT819 demonstrating durable SLEDAI-2K score reductions with no dose-limiting toxicities or graft-versus-host disease, extension of its partnership with Ono Pharmaceutical, plans for a registrational study of FT819 in moderate-to-severe SLE and lupus nephritis in 2026 under RMAT discussions with the FDA, and a cash runway extended through fiscal 2027 supported by $249 million in cash, equivalents, and investments as of Q2 2025.

Company News

Company News APIChatGPT

  • globenewswire.com

    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

  • globenewswire.com

    Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

  • defenseworld.net

    CIRM backs Fate’s FT819 lupus trial

  • globenewswire.com

    Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

  • globenewswire.com

    Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026

  • globenewswire.com

    Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

  • globenewswire.com

    Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

  • defenseworld.net

    BlackRock Inc. Makes New Investment in Fate Therapeutics, Inc. $FATE

  • seekingalpha.com

    Fate Therapeutics: RECLAIM-LN Underway, Additional Clinical Updates Ahead

  • globenewswire.com

    Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

  • zacks.com

    Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates

  • globenewswire.com

    Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

  • youtube.com

    FATE UNKNOWN: If CLARITY DIES Democrats KILLED IT, Lummis says

  • globenewswire.com

    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

  • globenewswire.com

    Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

  • globenewswire.com

    Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

  • globenewswire.com

    Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

  • globenewswire.com

    Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

  • seekingalpha.com

    Fate Therapeutics: FT819 Progress Keeps My Bull Case Alive

  • globenewswire.com

    Fate Therapeutics Appoints Laura Hamill to Board of Directors